Pharmacologic Optimization of Voriconazole

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study proposal is to determine whether pharmacologic optimization of voriconazole by means of therapeutic drug monitoring (TDM) results in improved patient outcomes (efficacy and safety) and is more cost-effective compared to the current standard of care.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jan-Willem C Alffenaar; JWC Alffenaar
• Collaborators: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Erasmus Medical Center; Haga Hospital; Haga Hospital, Leyweg; Klinikum Oldenburg gGmbH; Leiden University Medical Center; Meander Medical Center; St. Antonius Hospital; UMC Utrecht; University Medical Center Nijmegen; VU University Medical Center
• Treatments: Voriconazole

Criteria

Inclusion Criteria:

• are at least 18 years of age

• have received chemotherapy for haematological malignancies or have received a hematopoietic stem cell transplant

• proven, probable or possible invasive fungal disease according to the EORTC/MSG criteria

• treatment with voriconazole

Exclusion Criteria:

• allergic to voriconazole or its excipients

• age below 18 years